UMB Bank’s Pacira BioSciences PCRX Stock Holding History

UMB Bank’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.1K	Buy	397 +14	+4%	+$331	﹤0.01%	1934
2026 Q1	$8.66K	Buy	383 +40	+12%	+$889	﹤0.01%	1909
2025 Q4	$8.88K	Buy	343 +20	+6%	+$476	﹤0.01%	1860
2025 Q3	$8.32K	Sell	323 -118	-27%	-$2.9K	﹤0.01%	1747
2025 Q2	$10.5K	Sell	441 -2	-0.5%	-$50	﹤0.01%	1586
2025 Q1	$11K	Buy	443 +66	+18%	+$1.58K	﹤0.01%	1516
2024 Q4	$7.1K	Buy	377 +74	+24%	+$1.3K	﹤0.01%	1591
2024 Q3	$4.56K	Sell	303 -72	-19%	-$1.23K	﹤0.01%	1760
2024 Q2	$10.7K	Buy	375 +31	+9%	+$882	﹤0.01%	1253
2024 Q1	$10.1K	Buy	344 +20	+6%	+$614	﹤0.01%	1275
2023 Q4	$10.9K	Sell	324 -272	-46%	-$7.96K	﹤0.01%	1263
2023 Q3	$18.3K	Hold	596	–	–	﹤0.01%	1108
2023 Q2	$23.9K	Hold	596	–	–	﹤0.01%	1051
2023 Q1	$24.3K	Hold	596	–	–	﹤0.01%	1035
2022 Q4	$23K	Hold	596	–	–	﹤0.01%	1073
2022 Q3	$32K	Buy	596 +30	+5%	+$1.67K	﹤0.01%	976
2022 Q2	$33K	Hold	566	–	–	﹤0.01%	1017
2022 Q1	$43K	Buy	566 +149	+36%	+$9.93K	﹤0.01%	1010
2021 Q4	$25K	Buy	+417	New	+$23K	﹤0.01%	1206

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UMB Bank's PCRX Position: Q2 2026 in Review

UMB Bank increased its Pacira BioSciences (PCRX) stake by 3.7% in Q2 2026, buying an estimated $331 and bringing the position to 397 shares worth $10.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1934.

UMB Bank first reported a position in PCRX in Q4 2021 and has held it in 19 quarters since. The position peaked at $43K in Q1 2022. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

UMB Bank held 397 shares of Pacira BioSciences worth $10.1K as of Q2 2026.
UMB Bank bought 14 Pacira BioSciences shares in Q2 2026, an estimated $331.
Pacira BioSciences made up ﹤0.01% of UMB Bank's portfolio in Q2 2026, its #1934 holding.
UMB Bank first reported a position in Pacira BioSciences in Q4 2021 and has held it in 19 quarters since.
UMB Bank's Pacira BioSciences position peaked at $43K in Q1 2022.
254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on UMB Bank's 13F filing for Q2 2026, filed 13 Aug 2026.